Literature DB >> 30545627

Structural and functional properties of αβ-heterodimers of tropomyosin with myopathic mutations Q147P and K49del in the β-chain.

Alexander M Matyushenko1, Daniil V Shchepkin2, Denis S Susorov3, Victoria V Nefedova3, Galina V Kopylova2, Valentina Y Berg2, Sergey Y Kleymenov4, Dmitrii I Levitsky5.   

Abstract

Tropomyosin (Tpm) is an α-helical coiled-coil actin-binding protein that plays a key role in the Ca2+-regulated contraction of striated muscles. Two Tpm isoforms, α (Tpm 1.1) and β (Tpm 2.2), are expressed in fast skeletal muscles. These Tpm isoforms can form either αα and ββ homodimers, or αβ heterodimers. However, only αα-Tpm and αβ-Tpm dimers are usually present in most of fast skeletal muscles, because ββ-homodimers are relatively unstable and cannot exist under physiologic conditions. Nevertheless, the most of previous studies of myopathy-causing mutations in the Tpm β-chains were performed on the ββ-homodimers. In the present work, we applied different methods to investigate the effects of two myopathic mutations in the β-chain, Q147P and K49del (i.e. deletion of Lys49), on structural and functional properties of Tpm αβ-heterodimers and to compare them with the properties of ββ-homodimers carrying these mutations in both β-chains. The results show that the properties of αβ-Tpm heterodimers with these mutations in the β-chain differ significantly from the properties of ββ-homodimers with the same substitutions in both β-chains. This indicates that the αβ-heterodimer is a more appropriate model for studying the effects of myopathic mutations in the β-chain of Tpm than the ββ-homodimer which virtually does not exist in human skeletal muscles.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ca(2+)-regulation of muscle contraction; Differential scanning calorimetry; In vitro motility assay; Myopathic mutations; Tropomyosin; αβ-heterodimers

Mesh:

Substances:

Year:  2018        PMID: 30545627     DOI: 10.1016/j.bbrc.2018.12.019

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  5 in total

1.  Congenital myopathy-related mutations in tropomyosin disrupt regulatory function through altered actin affinity and tropomodulin binding.

Authors:  Joanna Moraczewska; Katarzyna Robaszkiewicz; Małgorzata Śliwinska; Marta Czajkowska; Thu Ly; Alla Kostyukova; Han Wen; Wenjun Zheng
Journal:  FEBS J       Date:  2019-03-05       Impact factor: 5.542

Review 2.  Functional outcomes of structural peculiarities of striated muscle tropomyosin.

Authors:  Galina V Kopylova; Alexander M Matyushenko; Natalia A Koubassova; Daniil V Shchepkin; Sergey Y Bershitsky; Dmitrii I Levitsky; Andrey K Tsaturyan
Journal:  J Muscle Res Cell Motil       Date:  2019-09-18       Impact factor: 2.698

3.  Looking for Targets to Restore the Contractile Function in Congenital Myopathy Caused by Gln147Pro Tropomyosin.

Authors:  Olga E Karpicheva; Armen O Simonyan; Nikita A Rysev; Charles S Redwood; Yurii S Borovikov
Journal:  Int J Mol Sci       Date:  2020-10-14       Impact factor: 5.923

4.  A pathogenic mechanism associated with myopathies and structural birth defects involves TPM2-directed myogenesis.

Authors:  Jennifer McAdow; Shuo Yang; Tiffany Ou; Gary Huang; Matthew B Dobbs; Christina A Gurnett; Michael J Greenberg; Aaron N Johnson
Journal:  JCI Insight       Date:  2022-06-22

5.  Impact of A134 and E218 Amino Acid Residues of Tropomyosin on Its Flexibility and Function.

Authors:  Marina A Marchenko; Victoria V Nefedova; Daria S Yampolskaya; Galina V Kopylova; Daniil V Shchepkin; Sergey Y Bershitsky; Natalia A Koubassova; Andrey K Tsaturyan; Dmitrii I Levitsky; Alexander M Matyushenko
Journal:  Int J Mol Sci       Date:  2020-11-18       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.